MDM4
MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.
Overview
Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains. Inhibits degradation of MDM2.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Nivolumab, Pembrolizumab and Atezolizumab. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.60, somatic mutation 0.97, animal model 0.49).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.
- 1 · What it is
MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.
- 2 · What goes wrong in cancer
Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains.
- 3 · How drugs use it
No product in this corpus aims at MDM4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:6974 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15151 (protein name, function text, keywords and locations (REST API)); CIViC gene MDM4 (2 evidence items, 0 assertions, 2 variants; diseases: Cancer (GraphQL API, CC0)); Open Targets ENSG00000198625 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: prostate cancer 0.55, melanoma 0.59, skin cancer 0.56, breast cancer 0.55 (GraphQL API, CC0))
Biology
Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions. Location: Nucleus; Cytoplasm (UniProt). Locus 1q32.1 (HGNC).
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254)
- Prostate cancer: Open Targets association 0.55 with prostate cancer (MONDO_0008315)
- Melanoma: Open Targets association 0.59 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MDM4" OR ABSTRACT:"MDM4" OR TITLE:"MDM4 regulator of p53" OR ABSTRACT:"MDM4 regulator of p53") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MDM4, not a curated reading list.